Cited by — MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite MAIA frailty subgroup analysis: long-term follow-up with daratumumab plus lenalidomide/dexamethasone in transplant-ineligible newly diagnosed myeloma.
No admitted local citation edges point to this work yet.
